Johnson & Johnson (JNJ): A Cheap Robotics Stock Redefining Coronary Artery Disease Treatment

Johnson & Johnson (NYSE:JNJ) is one of the cheap robotics stocks to buy right now. On May 12, Johnson & Johnson (NYSE:JNJ) confirmed the global launch of the Shockwave C2 Aero Coronary IVL Catheter for the treatment of calcified coronary artery disease, as it seeks to redefine the standards of coronary IVL with efficient, predictable procedures.

Johnson & Johnson (JNJ): A Cheap Robotics Stock Redefining Coronary Artery Disease Treatment

Gil C/Shutterstock.com

The next-generation intravascular lithotripsy catheter features enhanced deliverability and lesion-crossing capabilities. It leverages ultrasonic acoustic pressure waves to disrupt calcified plaque in coronary arteries, extending Shockwave IVL’s clinically validated mechanism of action. It also features a flexible shaft balloon and marker brands to enhance navigation in tortuous arteries.

The Shockwave C2 Aero Coronary IVL Catheter enables Johnson & Johnson to target the 315 million people worldwide who are struggling with coronary artery disease. The company has already made the device available in the US and Japan. It also plans to make it available in Europe and Canada.

Earlier on May 5, Johnson & Johnson announced results from the first clinical study of its investigational OTTAVA Robotic Surgical System, showing that in a 30‑patient trial for Roux‑en‑Y gastric bypass all procedures were completed robotically without conversion, meeting safety and performance endpoints and achieving an average 30‑pound weight loss at 30 days.

The data, presented at the 2026 ASMBS Annual Meeting, supported an FDA De Novo application for OTTAVA to cover multiple upper‑abdominal procedures, highlighting its novel table‑integrated design that enables use in space‑constrained operating rooms and reinforces J&J’s commitment to advancing bariatric and general surgery through robotics innovation.

Johnson & Johnson (NYSE:JNJ) focuses on medical robotics and digital surgery. They are actively developing advanced surgical systems and data ecosystems to improve patient outcomes across general surgery, lung diagnostics, and orthopedics.

While we acknowledge the risk and potential of JNJ as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than JNJ and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Sin Stocks to Buy Now and 8 Best CBD Stocks to Buy Right Now.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1